Aurobindo Pharma, one of the leading drugmakers in India, has informed that it has received final approval from the US Food and Drug Administration (US FDA) for its Cefazolin injection in the strengths of 500 mg and 1 gram per vial.

According to the company, the injection is a Sterile Cephalosporin product under the anti-infective segment and is a generic equivalent to Abraxis Pharmaceutical Products' reference listed drug Cefazolin.

Aurobindo has 74 abbreviated new drug applications (ANDA) approved by the U. S. FDA.

Last week the pharmaceutical company had received US FDA approval to manufacture and market in US market, Alendronate Sodium tablets, used in the treatment of bone diseases.

In recent stock recommendations, Religare Securities has advised its clients to buy shares of Aurobindo Pharma for short term as the technical charts show bullish candle pattern.